MA32012B1 - Octahydroquinolizines destinees au traitement du diabete - Google Patents

Octahydroquinolizines destinees au traitement du diabete

Info

Publication number
MA32012B1
MA32012B1 MA33011A MA33011A MA32012B1 MA 32012 B1 MA32012 B1 MA 32012B1 MA 33011 A MA33011 A MA 33011A MA 33011 A MA33011 A MA 33011A MA 32012 B1 MA32012 B1 MA 32012B1
Authority
MA
Morocco
Prior art keywords
treatment
prevention
obesity
diabetes
compounds
Prior art date
Application number
MA33011A
Other languages
Arabic (ar)
English (en)
Inventor
Klaus Frobel
Clemens Fürnsinn
Immanuel Adorjan
Leonhardt Bauer
Original Assignee
55 Pharma Drug Discovery & Dev Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07450235A external-priority patent/EP2072515B1/fr
Application filed by 55 Pharma Drug Discovery & Dev Ag filed Critical 55 Pharma Drug Discovery & Dev Ag
Publication of MA32012B1 publication Critical patent/MA32012B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne de nouvelles octahydroquinolizines utilisées dans le traitement ou la prévention du diabetes mellitus et de ses complications, dans le traitement ou la prévention de l'hyperlipidémie, dans le traitement de la dyslipidémie diabétique, dans le traitement ou la prévention du syndrome métabolique, dans le traitement de maladies liées à un dysfonctionnement métabolique, et dans le traitement de l'obésité ou de maladies liées à l'obésité. L'invention se rapporte aussi à des compositions pharmaceutiques et à des trousses comprenant lesdits composés, seuls ou combinés à d'autres médicaments ou composés, qui ont pour objet d'offrir un traitement ou une prévention améliorés des maladies et syndromes précités chez des humains ou des animaux.
MA33011A 2007-12-19 2010-07-14 Octahydroquinolizines destinees au traitement du diabete MA32012B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07450235A EP2072515B1 (fr) 2007-12-19 2007-12-19 Quinazolidines substituées pour traitement antidiabétique
AT13152008 2008-08-25
PCT/AT2008/000458 WO2009076693A1 (fr) 2007-12-19 2008-12-17 Octahydroquinolizines destinées au traitement du diabète

Publications (1)

Publication Number Publication Date
MA32012B1 true MA32012B1 (fr) 2011-01-03

Family

ID=40430049

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33011A MA32012B1 (fr) 2007-12-19 2010-07-14 Octahydroquinolizines destinees au traitement du diabete

Country Status (16)

Country Link
US (1) US20110003808A1 (fr)
EP (1) EP2222673A1 (fr)
JP (1) JP2011506485A (fr)
KR (1) KR20100107469A (fr)
CN (1) CN101918402A (fr)
AP (1) AP2010005317A0 (fr)
AU (1) AU2008338287B2 (fr)
BR (1) BRPI0821160A2 (fr)
CA (1) CA2710006A1 (fr)
EA (1) EA201070750A1 (fr)
IL (1) IL205752A0 (fr)
MA (1) MA32012B1 (fr)
MX (1) MX2010006173A (fr)
NZ (1) NZ585307A (fr)
WO (1) WO2009076693A1 (fr)
ZA (1) ZA201003316B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2315766A1 (fr) * 2008-08-25 2011-05-04 55pharma Drug Discovery & Development AG Octahydroquinolizines destinées au traitement du diabète
JP6520440B2 (ja) * 2014-06-16 2019-05-29 有限会社バイオシステムコンサルティング 新規化合物
CN110746282A (zh) * 2019-11-04 2020-02-04 天津市安凯特科技发展有限公司 一种4-氯-2-丁酮的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795318B (en) * 1978-10-13 1980-09-24 Hoffmann La Roche Phenyl quinolizidines
US7538110B2 (en) * 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists

Also Published As

Publication number Publication date
BRPI0821160A2 (pt) 2015-06-16
CA2710006A1 (fr) 2009-06-25
AP2010005317A0 (en) 2010-08-31
JP2011506485A (ja) 2011-03-03
AU2008338287B2 (en) 2012-06-07
MX2010006173A (es) 2010-09-30
ZA201003316B (en) 2011-08-31
IL205752A0 (en) 2010-11-30
WO2009076693A1 (fr) 2009-06-25
AU2008338287A1 (en) 2009-06-25
CN101918402A (zh) 2010-12-15
EP2222673A1 (fr) 2010-09-01
US20110003808A1 (en) 2011-01-06
NZ585307A (en) 2011-11-25
KR20100107469A (ko) 2010-10-05
EA201070750A1 (ru) 2010-12-30

Similar Documents

Publication Publication Date Title
MA32397B1 (fr) Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
MA30875B1 (fr) Therapie de combinaison avec des inhibiteurs de sglt-2 et leurs compositions pharmaceutiques
MA46219A (fr) Composés de co-agonistes du glucagon et du glp-1
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
MA41083A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA34517B1 (fr) Promédicaments comprenant un conjugué exendine-lieur
CL2007003262A1 (es) Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades.
MA33743B1 (fr) Compositions comprenant du tramadol et du célécoxib dans le traitement de la douleur
MA30337B1 (fr) Anticorps
CL2011000867A1 (es) Formas cristalinas da, c y ii de (r)-5-[3-cloro-4-(2,3-dihidroxi-propoxi)- benz[z]ilideno]-2- ([z]- propilimino) -3-o- totil-tiazolidin-4-ona; composicion farmaceutica; y uso en el tratamiento o prevencion de rechazo de organos trasplantados, sindrome autoinmunitarios, asma, diabetes, cancer.
EA201070121A1 (ru) Лекарственная форма, содержащая слитый белок glp-1-fc
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
WO2006084176A3 (fr) Composes et compositions utilises comme modulateurs de ppar
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
MA32132B1 (fr) Utilisation de ranolazine pour traiter la douleur
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
MA33299B1 (fr) Nouvelle formulation de naproxène
WO2007056366A3 (fr) Composes et compositions utilises en tant que modulateurs des ppar
MA30903B1 (fr) Derives de 2 - phenyl-6-minocarbonyl-pyrimidine
MA29723B1 (fr) Composes
MA31941B1 (fr) Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine
MA33758B1 (fr) Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes